Anti-platelet therapy ( @entity117 250 mg/every other day approximately 1000 mg/day + @entity4341 150 mg/day) was performed on 51 @entity1 with @entity63 ( @entity63 ). Among these @entity1 , 41 cases showed no recurrence of @entity63 attack, whereas the remaining 10 cases had re-attacks. These 2 groups were compared from the viewpoint of various risk factors and other clinical findings: e.g. CT scan and angiographic appearance. But there was no statistically significant difference between them. Platelet aggregability and platelet survival time were examined in twenty-eight @entity1 out of cases. We used a simple nonradioisotope technic for the determination of platelet survival time. Platelet survival time was shortened in 22 of 28 (79%) @entity1 . On the other hand, @entity1423 was found to have no definite tendency. In 9 of 10 cases, platelet survival time was revealed to be prolonged several months after administration of anti-platelet drugs. There was no re-attack in 7 of these 9 @entity1 . Some reports also showed that platelet survival time was shortened in various @entity1031 and recovered by anti-platelet drugs. Measurement of platelet survival time is thought to be an important method as to the indication and the monitoring of anti-platelet therapy.

[Anti-platelet therapy in XXXX --clinical and hematological study].

@entity1 :: ('9606', 'Species') :: ['patients'] @entity1423 :: ('MESH:D001791', 'Disease') :: ['platelet aggregability'] @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemic cerebrovascular disorders', 'ICVD'] @entity117 :: ('MESH:D001241', 'Chemical') :: ['Aspirin'] @entity4341 :: ('MESH:D004176', 'Chemical') :: ['Dipyridamole'] @entity1031 :: ('MESH:D013923', 'Disease') :: ['thromboembolism']
@entity63 :: (MESH:D007511,Disease) :: ['ischemic cerebrovascular disorder']
